Abstract
Malignant lymphoma is a lymphocyte-derived neoplastic disease. The incidence of malignant lymphoma is increasing yearly. Increased levels of the soluble interleukin-2 receptor (sIL-2R) in peripheral blood have been found in patients with malignant lymphoma. Measured sIL-2R levels can be used as a biomarker for the diagnosis and follow-up of malignant lymphoma. In this study, we evaluated a newly developed reagent for the measurement of sIL-2R, “STACIA CLEIA IL-2R”. Satisfactory results were obtained in terms of precision, linearity, and sensitivity. No prozone phenomenon was observed, and there was no interference from substances such as free bilirubin, conjugated bilirubin, chyle, rheumatoid factor, and hemoglobin. Strong correlations were observed between serum and heparin lithium plasma samples (r = 0.999, y = 0.98x − 10.51), and between STACIA CLEIA IL-2R and Detamina CL IL-2R (r = 0.995, y = 1.02x − 173.97). However, there are cases of discrepancy in sIL-2R concentrations measured by STACIA CLEIA IL-2R and Detamina CL IL-2R. Analysis of the cause of the discrepancy using dithiothreitol revealed that false-positive results may originate from abnormal IgM in samples when analyzed using the Detamina CL IL-2R reagent. In summary, our results suggest that the newly developed STACIA CLEIA IL-2R reagent is useful for routine examinations.
